Skip to main
KTTA

KTTA Stock Forecast & Price Target

KTTA Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Pasithea Therapeutics is a company with a strong potential for growth due to its focus on treatments for central nervous system disorders and other diseases. With its innovative approach in the fields of neuroscience and drug development, the company has a promising pipeline of treatments for various diseases, including Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, and Schizophrenia. The recent amendment to the company's protocol for its Phase 1/1b trial of PAS-004, which allows for a longer on-treatment window and a more detailed assessment of tumor measurements, de-risks the program and strengthens its potential in the market. Additionally, the company's Rare Disease Designation and potential for a Priority Review Voucher from the FDA provide potential upside for the company and its investors. Overall, Pasithea Therapeutics' focus on meeting unmet needs in the market, coupled with its promising pipeline, make it a strong investment opportunity for the future.

Bears say

Pasithea Therapeutics is currently focused on researching and developing treatments for CNS disorders and other diseases such as RASopathies and certain cancers. However, its amended Phase 1/1b NF1-PN protocol to broaden Part A and the risk factors mentioned suggest potential challenges and uncertainties in the company's drug development progress and its future profitability, which may negatively impact the stock's performance. Additionally, the company's reliance on securing adequate funding and potential dilutive capital raises could further dampen the outlook for the stock.

KTTA has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pasithea Therapeutics Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pasithea Therapeutics Corp (KTTA) Forecast

Analysts have given KTTA a Strong Buy based on their latest research and market trends.

According to 1 analysts, KTTA has a Strong Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pasithea Therapeutics Corp (KTTA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.